IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v25y2007i10p881-897.html
   My bibliography  Save this article

Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin

Author

Listed:
  • Neale Cohen
  • Michael Minshall
  • Lyn Sharon-Nash
  • Katerina Zakrzewska
  • William Valentine
  • Andrew Palmer

Abstract

Background: Recent meta-analyses in the published medical literature have found improved glycaemic control with continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) of insulin for patients with diabetes mellitus. In Australia, CSII is predominantly used in type 1 diabetes mellitus (T1DM) patient populations. Objective/intervention: To project long-term costs and outcomes of CSII (Novorapid® or Humalog®) compared with MDI (NPH insulin plus Novorapid® or Humalog®) in adult and adolescent T1DM patients in Australia. Methods: The study was a modelling analysis utilising a lifetime horizon in adult and adolescent specialty care T1DM patient populations from Australia. Published Australian diabetes complication costs (adjusted to Australian dollars [$A], year 2006 values), treatment costs and discount rates of 5.0% per annum were applied to costs and clinical outcomes. A lifetime horizon was taken, considering only direct medical costs and excluding indirect and non-medical costs. The validated CORE diabetes model employs standard Markov/Monte Carlo simulation techniques. It was used to simulate diabetes progression in Australian adult (mean age 43 years, duration of diabetes 17 years, mean glycosylated haemoglobin [HbA 1c ] 8.2%) and adolescent (mean age 17 years, duration of diabetes 6 years, mean HbA1c 8.9%) patients with baseline characteristics taken predominantly from Australian National Diabetes Information Audit and Benchmarking (ANDIAB) in Australia. The main outcome measures were incremental costs and effectiveness of CSII compared with MDI in Australian adult and adolescent patients with T1DM. Results: Mean direct lifetime costs were $A34 642 higher with CSII treatment than with MDI for adult patients and $A41 779 higher for adolescent patients. Treatment with CSII was associated with an improvement in life expectancy of 0.393 years for adults compared with MDI and 0.537 years for adolescents. The corresponding gains in QALYs were 0.467 QALYs and 0.560 QALYs for adults and adolescents, respectively. This produced incremental cost effectiveness ratios (ICERs) of $A88 220 and $A77 851 per life-year gained for CSII compared with MDI for adult and adolescent T1DM patients, respectively, in Australia. These data also produced corresponding ICERs of $A74 147 per QALY and $A74 661/QALY for adult and adolescent T1DM patients, respectively. Sensitivity analyses suggested that our base-case assumptions were mostly robust with improvements in ICERs for reduction in hypoglycaemic events with CSII treatment and worse ICERs for lower HbA1c changes associated with CSII treatment compared with MDI. Conclusions: Our analysis suggests that CSII is associated with ICERs in the range of $A53 022–259 646 per QALY gained, with most ICERs representing good value for money in Australia under the majority of scenarios explored. Copyright Adis Data Information BV 2007

Suggested Citation

  • Neale Cohen & Michael Minshall & Lyn Sharon-Nash & Katerina Zakrzewska & William Valentine & Andrew Palmer, 2007. "Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin," PharmacoEconomics, Springer, vol. 25(10), pages 881-897, October.
    • Handle: RePEc:spr:pharme:v:25:y:2007:i:10:p:881-897
    DOI: 10.2165/00019053-200725100-00006
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200725100-00006
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200725100-00006?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Philip Clarke & Alastair Gray & Rury Holman, 2002. "Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)," Medical Decision Making, , vol. 22(4), pages 340-349, August.
    2. Elkan F. Halpern & Milton C. Weinstein & Maria G.M. Hunink & G. Scott Gazelle, 2000. "Representing Both First- and Second-order Uncertainties by Monte Carlo Simulation for Groups of Patients," Medical Decision Making, , vol. 20(3), pages 314-322, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Sandra Tunis & Luc Sauriol & Michael Minshall, 2010. "Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada," Applied Health Economics and Health Policy, Springer, vol. 8(4), pages 267-280, July.
    2. Montserrat Vera-Llonch & Ellen Dukes & Javier Rejas & Oleg Sofrygin & Marko Mychaskiw & Gerry Oster, 2010. "Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 35-44, February.
    3. Mason, J.E. & Denton, B.T. & Shah, N.D. & Smith, S.A., 2014. "Optimizing the simultaneous management of blood pressure and cholesterol for type 2 diabetes patients," European Journal of Operational Research, Elsevier, vol. 233(3), pages 727-738.
    4. Elizabeth G Bond & Lusine Abrahamyan & Mohammad K A Khan & Andrea Gershon & Murray Krahn & Ping Li & Rajibul Mian & Nicholas Mitsakakis & Mohsen Sadatsafavi & Teresa To & Petros Pechlivanoglou & for t, 2020. "Understanding resource utilization and mortality in COPD to support policy making: A microsimulation study," PLOS ONE, Public Library of Science, vol. 15(8), pages 1-16, August.
    5. Mehdi Najafzadeh & Carlo Marra & Eleni Galanis & David Patrick, 2009. "Cost Effectiveness of Herpes Zoster Vaccine in Canada," PharmacoEconomics, Springer, vol. 27(12), pages 991-1004, December.
    6. Niklas Zethraeus & Magnus Johannesson & Bengt Jönsson & Mickael Löthgren & Magnus Tambour, 2003. "Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies," PharmacoEconomics, Springer, vol. 21(1), pages 39-48, January.
    7. Antonio García-Ruiz & Lucía Pérez-Costillas & Ana Montesinos & Javier Alcalde & Itziar Oyagüez & Miguel Casado, 2012. "Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses," Health Economics Review, Springer, vol. 2(1), pages 1-12, December.
    8. Maria Alva & Alastair Gray & Borislava Mihaylova & Philip Clarke, 2014. "The Effect Of Diabetes Complications On Health‐Related Quality Of Life: The Importance Of Longitudinal Data To Address Patient Heterogeneity," Health Economics, John Wiley & Sons, Ltd., vol. 23(4), pages 487-500, April.
    9. Brian T. Denton & Murat Kurt & Nilay D. Shah & Sandra C. Bryant & Steven A. Smith, 2009. "Optimizing the Start Time of Statin Therapy for Patients with Diabetes," Medical Decision Making, , vol. 29(3), pages 351-367, May.
    10. Adrian Bagust & Sophie Beale, 2005. "Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 data," Health Economics, John Wiley & Sons, Ltd., vol. 14(3), pages 217-230, March.
    11. Shuyan Gu & Yuhang Zeng & Demin Yu & Xiaoqian Hu & Hengjin Dong, 2016. "Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-21, November.
    12. Sankararaman, S. & Mahadevan, S., 2013. "Separating the contributions of variability and parameter uncertainty in probability distributions," Reliability Engineering and System Safety, Elsevier, vol. 112(C), pages 187-199.
    13. Shuyan Gu & Yiming Mu & Suodi Zhai & Yuhang Zeng & Xuemei Zhen & Hengjin Dong, 2016. "Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-25, November.
    14. Vinaytosh Mishra & Mohita G. Sharma, 2020. "Understanding Humanitarian Supply Chain Through Causal Modelling," South Asian Journal of Business and Management Cases, , vol. 9(3), pages 317-329, December.
    15. Sarazin, Gabriel & Morio, Jérôme & Lagnoux, Agnès & Balesdent, Mathieu & Brevault, Loïc, 2021. "Reliability-oriented sensitivity analysis in presence of data-driven epistemic uncertainty," Reliability Engineering and System Safety, Elsevier, vol. 215(C).
    16. Mengjun Wu & John Brazier & Benjamin Kearns & Clare Relton & Christine Smith & Cindy Cooper, 2015. "Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 141-151, March.
    17. Sankararaman, Shankar & Mahadevan, Sankaran, 2011. "Likelihood-based representation of epistemic uncertainty due to sparse point data and/or interval data," Reliability Engineering and System Safety, Elsevier, vol. 96(7), pages 814-824.
    18. Irina Odnoletkova & Dirk Ramaekers & Frank Nobels & Geert Goderis & Bert Aertgeerts & Lieven Annemans, 2016. "Delivering Diabetes Education through Nurse-Led Telecoaching. Cost-Effectiveness Analysis," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-18, October.
    19. Aliasghar A. Kiadaliri & Ulf-G Gerdtham & Björn Eliasson & Soffia Gudbjörnsdottir & Ann-Marie Svensson & Katarina Steen Carlsson, 2014. "Health Utilities of Type 2 Diabetes-Related Complications: A Cross-Sectional Study in Sweden," IJERPH, MDPI, vol. 11(5), pages 1-14, May.
    20. John Yfantopoulos & Athanasios Chantzaras, 2020. "Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(5), pages 729-743, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:25:y:2007:i:10:p:881-897. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.